Gregg Sonnen

Gregg Sonnen is Partner and CFO of KMG Capital Partners, a Colorado-based healthcare investment firm whose team is composed of executives with senior operating experience in healthcare companies. KMG is listed with a Lakewood, Colorado office and a focus on early-stage life sciences and healthcare investments.

Sonnen’s operating background is heavily finance- and healthcare-oriented. PCI | HealthDev’s board biography states that he has managed finance, accounting, treasury, financial planning and analysis, reporting, capital structure, IT/control systems, strategic investment evaluation, SEC matters, and M&A.

Before KMG and related board roles, Sonnen served as Senior Vice President and Chief Accounting Officer at First Data Corporation. First Data’s 2008 SEC filing says Sonnen was appointed SVP and Chief Accounting Officer effective May 1, 2008, after previously serving as SVP and Corporate CFO from September 2005. PCI | HealthDev notes that he was an executive lead in First Data’s spin-out of Western Union and the sale of First Data to KKR.

Earlier, Sonnen spent more than 10 years at Gambro Healthcare and affiliated companies, including as Senior VP/CFO. He began his career with 13 years at Ernst & Young and predecessor Arthur Young. His LinkedIn profile lists KMG Capital Partners, Denver, Colorado, and University of Notre Dame education from 1977 to 1981.

• KMG focuses on healthcare opportunities rather than generalist angel investing. Public profiles describe the firm as targeting healthcare services, healthcare real estate development, biosimilars, medical devices and diagnostics, and internet-based healthcare solutions.
• The firm appears comfortable with early-stage and growth-stage healthcare businesses. Massinvestor lists KMG’s stage as “Early,” while CB Insights shows KMG participating in Series A, Series B, Series C, Series D, and Series D-II financings for portfolio companies.
• KMG’s stated portfolio approach is long-term and operationally involved: building a “long-term portfolio of healthcare companies” with attractive models, service concepts, technologies, and management teams.
• KMG appears to favor companies where the partners’ healthcare operating backgrounds are relevant, including clinical trials, physician/patient engagement, medical devices, healthcare facilities, and digital health.
• In Wildflower Health’s Series A announcement, KMG partner Kerry Hicks framed the investment around healthcare mobility and enterprise adoption: “Mobile in healthcare is exploding” and Wildflower could become a leading maternity solution.
• Massinvestor describes KMG’s core-company approach as emphasizing free cash flow generation, long-term value creation, and an ownership structure of 25% or greater for core operating companies.